Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.

@article{Holtan2015CompositeEP,
  title={Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation.},
  author={Shernan Grace Holtan and Todd E Defor and Aleksander Lazaryan and Nelli Bejanyan and Mukta Arora and Claudio G Brunstein and Bruce R Blazar and Margaret L Macmillan and Daniel J. Weisdorf},
  journal={Blood},
  year={2015},
  volume={125 8},
  pages={1333-8}
}
The success of allogeneic hematopoietic cell transplantation (HCT) is typically assessed as individual complications, including graft-versus-host disease (GVHD), relapse, or death, yet no one factor can completely characterize cure without ongoing morbidity. We examined a novel composite end point of GVHD-free/relapse-free survival (GRFS) in which events include grade 3-4 acute GVHD, systemic therapy-requiring chronic GVHD, relapse, or death in the first post-HCT year. In 907 consecutive… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 68 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 22 references

Regression models and life tables

  • DR Cox
  • J R Stat Soc,
  • 1972
Highly Influential
9 Excerpts

A multicenter phase II trial randomizing novel approaches for graft-versus-host disease prevention compared to contemporary controls (1203)

  • J Bolanos-Meade, J Koreth, R. Reshef
  • Available at: https://clinicaltrials.gov/ct2/show…
  • 2015
2 Excerpts

Use of composite endpoints in clinical trials

  • AJ Sankoh, H Li, RB Sr.D’Agostino
  • Stat Med
  • 2014
1 Excerpt

Current use and outcome of hematopoietic stem cell transplantation: CIBMTR

  • MC Pasquini, Z. Wang
  • Summary Slides,
  • 2013
1 Excerpt

Similar Papers

Loading similar papers…